At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials enrollment ending with over 10,000 participants, the company is waiting for approval.
With govt's local clinical trials waiver for certain drugs and vaccines, Japanese firm Takeda may soon launch QDenga, which will be a boost for India’s fight against dengue.
Study raises need for vaccines to protect those who have not been infected. 619 children in 3 hospitals across India were part of study, published in Nature Medicine in February.
Takeda's QDENGA, designed to protect against all 4 dengue virus serotypes, has been recommended by Strategic Advisory Group of Experts on Immunization for use in endemic countries.
American objectives are unmet. They neither have muscle nor motivation to resume the war. As for Iran, the regime didn’t just survive, it’s now led by more radical individuals.
COMMENTS